Meera Berry

Title: Meera Berry: Innovator in Pharmaceutical Antibody Development

Introduction

Meera Berry is a prominent inventor based in Ulm, Germany, known for her significant contributions to the field of pharmaceutical compositions. With a total of four patents to her name, she has made remarkable strides in the development of bispecific antibodies aimed at treating tumorous diseases.

Latest Patents

One of her latest patents is a pharmaceutical composition comprising a bispecific antibody for EpCAM. This invention provides a bispecific single chain antibody construct characterized by at least two domains. One domain specifically binds to human EpCAM and includes a CDR-H3 region with the amino acid sequence NXID antigen, while the second domain binds to the human CD3 antigen. The invention also outlines a process for producing this pharmaceutical composition, along with methods for preventing, treating, or ameliorating tumorous diseases using the disclosed bispecific single chain antibody construct. Another notable patent involves human-anti-human CD3 binding molecules, which details a method for preparing a human binding molecule that specifically binds to the human CD3 complex.

Career Highlights

Throughout her career, Meera Berry has worked with notable companies such as Micromet AG and Amgen Research (Munich) GmbH. Her work in these organizations has contributed to advancements in antibody research and development, further establishing her reputation in the pharmaceutical industry.

Collaborations

Meera has collaborated with esteemed colleagues, including Peter Kufer and Tobias Raum, enhancing her research and innovation efforts in the field of biotechnology.

Conclusion

Meera Berry's innovative work in the development of bispecific antibodies showcases her dedication to advancing medical science. Her contributions are paving the way for new treatments in oncology, highlighting her importance as an inventor in the pharmaceutical sector.